BioFocus and Usher III Initiative, Inc. announce collaboration
“We are pleased to support the Usher III Initiative in its aim to find a targeted treatment and cure for Usher III,” said Angus MacLeod, Vice President, Medicinal Chemistry, BioFocus. “This collaboration will utilize BioFocus’ expertise in integrated drug discovery programs.”
Three subtypes of Usher Syndrome have been identified as I, II and III. The clinical symptoms and onset of the disease varies between the different subtypes: type I shows the most profound impact on hearing and vision, whereas type II and III are generally milder with onset occurring later in life.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.